Radioiodine for Graves disease in a breastfeeding mother who works in a daycare

No. Breastfeeding is an absolute contraindication to radioiodine therapy. The lactating breast expresses the sodium-iodide symporter, so 131I concentrates in breast tissue and in milk; the infant would receive a substantial thyroid dose with a real risk of permanent hypothyroidism and of thyroid malignancy. Pumping and discarding for a few days does not solve this, because the dose is retained in the gland and breast tissue far longer than a few days and because milk production must have ceased.

Before any activity is given, verify the following:

• Cessation of lactation. Confirm documented weaning and, ideally, that milk production has stopped for some weeks. Engorged, milk-containing breasts take up radioiodine, increasing breast dose and the risk of radiation mastitis.
• Pregnancy test. A negative serum or urine hCG within 24 to 48 hours of therapy, since she is only six months postpartum.
• No recent iodinated contrast. A recent contrast study would reduce uptake and, more importantly, indicates the uptake measurement may be unreliable.
• Informed consent and written instructions. She should understand the permanent loss of lactation and the necessary radiation safety measures.

The uptake study she already had also was not consistent with breastfeeding; that should be reviewed as a documentation and process issue.

Measure the dose rate at one meter and document it; commonly used discharge guidance is a dose rate below about 7 mR/h at one meter. Then give written, specific instructions tailored to a household with an infant and to childcare work:

• Distance and time. Sleep in a separate room for the first several days, avoid cosleeping and prolonged holding, and keep at least about one meter of distance where possible. Short, necessary caregiving is acceptable with precautions, but extended close contact is not.
• Home environment. Do not share utensils, towels or bedding; wash bedding and clothing separately; flush the toilet twice with the lid down and wash hands thoroughly.
• Incontinence. Sit to void, contain and double-bag incontinence products before disposal, wash hands, and change clothing if soiled. Her incontinence means more contamination control than a typical patient needs.
• Work. Notify the employer; the daycare job involves holding infants at close range, so she needs a period of modified duty or leave, with duration guided by the measured dose rate and the total activity rather than a fixed habit.
• Follow-up. Return for a dose-rate check, keep well hydrated, void frequently, and avoid pregnancy for at least six months.

Give the instructions in writing and confirm understanding, since the infant and the workplace are precisely where informal advice fails.

Defer radioiodine. Do not negotiate the contraindication: the risk to the infant is not acceptable, and there is no safe way to perform 131I therapy while she is lactating.

Options to discuss:

• Antithyroid drugs while breastfeeding. Low-to-moderate doses of methimazole (roughly 20 to 30 mg/day or less) or propylthiouracil are considered compatible with breastfeeding, so she can be treated medically and continue nursing. Beta-blockade with propranolol can continue for symptoms.
• Definitive surgery. Thyroidectomy is a reasonable option if she wants definitive treatment without radioiodine, with the usual surgical and anesthetic counseling.
• Radioiodine later. She can return for 131I after she has weaned and completed her family plans, provided she understands that pregnancy must be avoided for at least six months after therapy.

Counsel her that the delay is not a denial of care but a sequencing decision, and record the discussion. Also address her question directly: pumping and discarding is appropriate advice for some short-lived radiopharmaceuticals, but it is not adequate for radioiodine therapy, and saying so plainly prevents a dangerous misunderstanding.